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PathogenesisBalancing mitophagy and mitochondrial biogenesis is essential for maintaining a healthy population of mito-
chondria and cellular homeostasis. Coordinated interplay between these two forces that govern mitochondrial
turnover plays an important role as an adaptive response against various cellular stresses that can compromise
cell survival. Failure tomaintain the critical balance betweenmitophagy andmitochondrial biogenesis or homeo-
static turnover of mitochondria results in a population of dysfunctional mitochondria that contribute to various
disease processes. In this reviewwe outline themechanics and relationships betweenmitophagy andmitochon-
drial biogenesis, and discuss the implications of a disrupted balance between these two forces, with an emphasis
on cardiac physiology. This article is part of a Special Issue entitled "Mitochondria: From Basic Mitochondrial
Biology to Cardiovascular Disease".
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Mitochondria function as cellular power plants essential for meeting
the energetic demands of eukaryotic cells. Their role extends to reg-
ulating fuel utilization, calcium stores, intracellular signaling and cell
death. Because of the broad range of cellular functions they are involved
in,mitochondria inherently occupy an important position asmediators of
cellular homeostasis. Consequently, this crucial position associates the
dysfunction of mitochondria to the development of various humantute, 127 S. San Vicente Blvd.
2556.
eb).
. This is an open access article underdiseases. Notably, studies to dissect the etiology of Parkinson Disease
(PD) were among the ﬁrst to highlight the physiological consequence
of having poor mitochondrial quality control. Genetic models strongly
implicatemitochondrial dysfunction as a common feature in the develop-
ment of this neurodegenerative disease that leads to the loss of dopami-
nergic neurons (reviewed in [1–5]). In support of this is the fact that aging
increases the risk of developing PD, which correlates with higher inci-
dence of mitochondrial DNA mutations in dopaminergic neurons [6].
Moreover, agents that induce mitochondrial toxicity have been shown
to lead to PD-like symptoms in animal models [7].
Themajor chronic diseaseswe face today such as neurodegenerative
diseases, cancer, aging, diabetes, and heart failure are accompanied by
mitochondrial dysfunction, and in fact, many elements of these chronicthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Mitochondrial disorders may be inherited either through maternal
transmission of an abnormal mitochondrial genome or through autoso-
mal transmission of mutations in the nuclear-encoded mitochondrial
genes. However, far more commonly, mitochondrial dysfunction is a
consequence of derangements in the ordinarily robust systems that or-
chestrate andmaintain the health and function of these vital organelles.
Mitochondrial quality control collectively describes the cellular sys-
tems used tomaintain a population of optimally-functioningmitochon-
dria. Mitochondria possess an internal protein quality control system to
refold or eliminate misfolded proteins, comprising chaperones (Hps10,
Hsp60 and others) and proteases (Lon and other AAA proteases).
Import of nuclear-encoded proteins must be coordinated with the ex-
pression of mitochondrial subunits for proper assembly of oxidative
phosphorylation (OXPHOS) complexes. Homeostatic control of this is
mediated through the mitochondrial unfolded protein response
(UPRmt), which is activated by an imbalance of nuclear vs. mitochon-
drial OXPHOS subunits [9]. Mitochondrial turnover is another integral
aspect of quality control in which dysfunctional mitochondria are se-
lectively eliminated through autophagy (mitophagy) and replaced
through the expansion of preexisting mitochondria (biogenesis). Im-
paired mitochondrial quality control results in the accumulation of dam-
aged mitochondria that may generate more reactive oxygen species
(ROS), produce ATP less efﬁciently, have a lower threshold for cyto-
chrome c release (apoptosis) or mitochondrial permeability transition
pore (MPTP) opening (necrosis), or may release mitochondrial compo-
nents (mtHSP60, oxidized mitochondrial DNA) into cytosol where its
recognition by receptors for damage-associated molecular patterns
(DAMP) activates inﬂammation. In this way, impaired mitochondrial
quality control gives rise to a myriad of disease states. Mitochondrial
quality control is critically dependent on autophagy; factors that impair
autophagy, such as advanced age or the metabolic syndrome (MetS),
will impact mitochondrial quality control and accelerate the develop-
ment of chronic disease phenotypes. In this review, we focus on the
mechanics of mitophagy and mitochondrial biogenesis, and discuss the
interplay between these two forces. We then discuss the pathophysio-
logical consequences with an emphasis on the heart.2. Mechanics of mitophagy and mitochondrial biogenesis
2.1. Mechanics of mitophagy
Autophagy is a lysosome-dependent cellular degradation system in
eukaryotic cells that allows for the bulk recycling of unwanted cytoplas-
mic aggregate proteins or dysfunctional organelles [10]. Along with the
ubiquitin proteasome system (UPS), autophagy is important for main-
taining proteostasis in the heart [11]. Mitophagy is the selective targeting
and removal of mitochondria through autophagy. While some authors
refer to the general process as mitochondrial autophagy and use the
termmitophagy tomean Parkin-dependent elimination of mitochondria,
in this review we will use ‘mitophagy’ to indicate autophagic removal of
mitochondria, and where appropriate, will specify Parkin-dependent
mitophagy. Mitophagy plays a critical role in protecting the heart during
ischemia/reperfusion injury [12–14]. Depolarization of mitochondria is a
prerequisite for Parkin-dependent mitophagy, but mitophagy mediated
by Bnip3 and NIX may be triggered through other pathways including
reactive oxygen species (ROS) [15], which promote dimerization of
Bnip3 (and potentially NIX) on the mitochondrial outer membrane
[16]. Nutrient stress (fasting) activates AMPK and general autophagy,
which is associated with production of ROS frommitochondrial complex
I [17]; however, fasting-induced mitophagy is impaired in cyclophilin
D-deﬁcient mice [18], which have hyperpolarized mitochondria. Thus
there are hints that mitophagy initiated by nutrient stress may be
initiated by mitochondrial depolarization and Parkin translocation, but
a role for ROS and Bnip3 is not excluded.Parkin-dependent (macro)mitophagy has been commonly studied
using chemical uncouplers of mitochondria such as carbonyl cyanide
4-(triﬂuoromethoxy) phenylhydrazone (FCCP) or carbonyl cyanide
m-chlorophenyl hydrazone (CCCP). Cellular stresses such as ischemia
also triggermitochondrial depolarization [13], resulting in the stabiliza-
tion of the serine/threonine kinase phosphatase and tensin homologue
(PTEN)-induced kinase 1 (PINK1) on the outermitochondrial membrane
(OMM) and recruitment of the E3 ubiquitin ligase Parkin, key factors for
mitophagy [19–22]. PINK1 and Parkin function as critical partners to
mediate the clearance of dysfunctional mitochondria [23,24]. Another
Parkin-dependent mechanism for degrading mitochondrial components
is through mitochondria-derived vesicles (MDV), which transit to
multivesicular bodies and eventually the lysosome, or to the peroxisome
[25].
Mitochondrial dynamics (fusion and ﬁssion) also play a critical role
in mitochondrial quality control, and the process is closely linked to
mitophagy, where ﬁssion is favored and fusion is suppressed, enabling
engulfment by autophagosomes. Fission of reticulate mitochondria
into smaller fragments is essential for mitophagy to occur [26,27]. Key
to this process is the dynamin-related protein 1 (Drp1), a GTPase in the
dynamin super-family of proteins, which is recruited to themitochondria
and facilitates the process of mitochondrial fragmentation [28]. Fission 1
(Fis1) is another key player in mitochondrial dynamics that interacts
with Drp1 to facilitate mitochondria fragmentation [29]. Mfn1 and 2,
which promote OMM fusion, are ubiquitinated and targeted for elimina-
tion by the UPS. Optic atrophy protein 1 (OPA1), important for fusion of
the inner mitochondrial membrane, is degraded during mitophagy by
the inner membrane zincmetalloprotease OMA1, which has overlapping
activity with matrix AAA proteases [30–32].
PINK1 is constitutively made and continuously degraded by the
mitochondria-speciﬁc proteases presenilin-associated rhomboid-like
protein (PARL) and mitochondrial processing peptidase (MPP). Loss of
membrane potential across the inner mitochondrial membrane inacti-
vates PARL and MPP through an uncharacterized mechanism and per-
mits the accumulation of PINK1 on the OMM. The kinase domain of
PINK1 faces the cytosol and phosphorylates OMM proteins facilitating
the recruitment of the E3-ubiquitin ligase Parkin [33–35]. PINK1 has
been reported to phosphorylate a number of targets including Parkin it-
self [36,37], mitofusin 2 (Mfn2) [15], and mitochondrial rho 1 (MIRO)
[38], a component of the microtubule-associated motor complex that
anchors kinesin to mitochondria. Mfn2, which functions in mitochon-
drial fusion events and links endoplasmic reticulum to mitochondria,
functions as a Parkin receptor after phosphorylation by PINK1, thereby
recruiting Parkin to the mitochondria, where it ubiquitinates a number
of OMM targets. Voltage-dependent anion channel 1 (VDAC1) has been
shown to be a Parkin target essential for mitophagy [19], although this
ﬁnding has been contested [39]. Ubiquitination and proteasomal degra-
dation ofMIRO,Mfn2, andMfn1 serve to immobilize themitochondrion
and prevent it from rejoining themitochondrial network through fusion
[15,38,40–42]. Ubiquitination of OMM proteins facilitates recruitment
of autophagy adapter proteins such as neighbor of BRCA1 (NBR1) or
sequestosome-1 (p62/SQSTM1). These bifunctional adaptor proteins
have an ubiquitin binding domain (UBA) and microtubule-associated
protein 1 light chain 3 (LC3) interacting region (LIR) to bring the develop-
ing autophagosomal membrane in proximity to the tagged mitochondri-
on in a zipper-like process [43,44]. SMAD-speciﬁc E3 ubiquitin ligase 1
(SMURF1) has also been linked to Parkin-dependent mitophagy [45].
Surprisingly, its ability to facilitate mitophagy has been found to be inde-
pendent of its E3 ubiquitin ligase function. Another Parkin-interacting au-
tophagy promoter, activating molecule in Beclin 1-regulated autophagy
(Ambra1) dissociates frommitochondrial Bcl-2 to bind Beclin1 to initiate
autophagy [46,47]. Ambra1 interacts with Parkin to promote mitophagy,
but is not a substrate of Parkin [48].
Mitophagy that is independent of PINK1/Parkin/ubiquitin can be
initiated through atypical members of the Bcl-2 homology domain 3
(BH3) family members such as BCL2/adenovirus E1B 19 kDa protein-
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interacting protein 3-like protein (BNIP3L aka NIX). These proteins
insert into the OMM and facilitate engulfment by the autophagosome
through a LIR domain that can interact with LC3 isoforms including
gamma-aminobutyric acid receptor-associated protein (GABARAP)
and GABARAP-like 1 (GABARAPL1) [49,50]. One study demonstrated
in cardiomyocytes that Bnip3 recruited Parkin and Drp1 to the mito-
chondria to promote ﬁssion and mitophagy [51]. In hypoxic conditions
mitophagy has been reported to be mediated by the OMM protein
FUN14 domain containing 1 (FUNDC1) which contains a LIR [52].
The process of mitophagy is rather complex and requires the co-
ordination of UPS-mediated degradation of outer membrane proteins
with autophagic engulfment of the remainder of the organelle. The
autophagosome,with its cargo, fuseswith a lysosome, forming the acid-
ic autophagolysosome. In cells in which the pH-sensitive ﬂuorescent
protein Keima is targeted to the mitochondria, one can monitor the
delivery of mitochondria to the autophagolysosome by monitoring the
pH-dependent shift in ﬂuorescence of mitoKeima [53]. The cargo is de-
graded by lysosomal hydrolases, liberating amino acids and fatty acids
which are exported to the cytosol via lysosomal permeases. A model
representing our current knowledge of the process of mitophagy is
shown in Fig. 1. While mitophagy is responsible for bulk degradation
of the organelle, turnover of individual components may proceed at
asynchronous rates through redistribution of components via fusion
events, selective degradation of proteins via mitochondrial proteases,
and proteasomal elimination of some outer membrane proteins. Even
in the case of Parkin-dependent mitophagy, some outer membraneFig. 1.Parkin-dependentmitochondrial autophagy (mitophagy). 1) Cellular stress, such as ische
low-membrane potential mitochondria from the rest of the network. Ischemia/reperfusion inju
and MPP, allowing for PINK1 stabilization on the OMM. 2) Parkin is recruited to the OMMwhe
degradation and targeted recognition of the ubiquitin-decoratedmitochondrion. 3) Autophagy
ubiquitinatedmitochondrion to thephagophore through interactionwith LC3 or homologues. 4)
form the autophagolysosomewhere ﬁnal degradation of bulk contents is completed. 5) Shaded
for autophagic clearance. These include Nix and Bnip3 which bind LC3 or homologues includinproteins are “rescued” through transfer to the ER [54]. Proteomic stud-
ies using heavy isotope labeling [55] revealed that proteins of the IMM
turn overwith rates that are similar tomitochondrial turnover based on
historic radiolabeling studies [56,57], suggesting that IMM proteins
(primarily OXPHOS constituents) may be primarily cleared via
mitophagy. This also corresponds to studies which showed that matrix
and OMMwere readily redistributed across themitochondrial network
when fusion and ﬁssion were intact; however, IMM constituents
redistributed much more slowly [27]. In contrast to the IMM proteins,
OM proteins turned over faster in many cases [55], possibly because
outer membrane proteins can be degraded by the UPS, by translocation
to other sites (ER or peroxisomes), by the MDV pathway, or by mito-
phagy. Matrix and IMM proteins have fewer routes of degradation:
while mitophagy predominates, matrix and IMM proteins can be
found in MDVs, and are substrates for Lon and other AAA proteases in
thematrix and intermembrane space. The rate of mitochondrial protein
turnover in mice is much slower in heart (mean half-life 17 days) than
in liver (4 days). A related study of mitochondrial protein synthesis in
rat comparing heart and liver using isotopic labeling and mass spec-
trometry also showed a 6-fold slower rate of turnover in the heart.
Turnover also varied according to subcellular location: protein turnover
was ~15% faster in subsarcolemmal mitochondria than in interﬁbrillar
mitochondria [58]. Mitochondrial protein import is inhomogeneous:
the ﬂuorescent MitoTimer protein revealed “hot spots” for synthesis
and import of this mitochondrially-targeted protein [59].
The importance of mitophagy in the heart was highlighted in our
previous work demonstrating the requirement for mitophagy inmia/reperfusion, triggers fragmentation of themitochondriamediatedbyDrp1, segregating
ry also leads to the collapse of mitochondrial membrane potential which deactivates PARL
re it binds Mfn2 and ubiquitinates multiple OMM proteins, marking them for proteasomal
adapter proteins such as p62 are then recruited to themitochondria which in turn bind the
Once the autophagosomehas fully engulfed themitochondrion, it fuseswith a lysosome to
area indicates atypical players that participate in recognition and targeting of mitochondria
g GABARAPL1.
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statin administration [12]. These results suggest that mitophagy is part
of the ﬁnal common pathway for various cardioprotective interventions,
and indeed, may be the ultimate effector. Beyond cardioprotection,
Parkin-dependent mitophagy plays a role in ischemia tolerance [60],
myocardial aging [61], and pathologic remodeling in response to pressure
overload [62]. The cardiac effects of Parkin deﬁciency are phenocopied by
PINK1 and Atg5 deletions [63,64]. Similarly, deletion of Mfn2, considered
an essential mitochondrial docking partner for Parkin, leads tomitochon-
drial dysfunction and heart failure [65]. These ﬁndings highlight the
importance of autophagy and mitophagy in cardiac function.
2.2. Overview of mitochondrial biogenesis
Mitochondrial biogenesis, which acts in concert with mitophagy to
maintain homeostasis in cells, depends on the coordination of nuclear
and mitochondrial-encoded gene expression. The nuclear-encoded
genes are primarily controlled by the transcription cofactor peroxisome
proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α)
[66]. First identiﬁed as a binding partner of peroxisome proliferator-
activated receptor γ (PPARγ) that increased its transcriptional activity
during thermogenesis, PGC-1α is a member of the nuclear receptor
superfamily of proteins that are responsible for assembling functional
macrocomplexes of transcriptional machinery at speciﬁc DNA se-
quences [67,68]. PGC-1α controls the expression of nuclear respiratory
factors 1 and 2 (NRF-1 and NRF-2), which in turn control the expression
of mitochondrial transcription factor A (Tfam) [69]. Tfam plays a key
role in mitochondrial biogenesis by regulating the expression of mito-
chondrial genes (tRNAs, rRNAs and 13 subunits of the respiratory
chain) from the heavy and light strands of the mitochondrial genome;
it is also essential for replication of mitochondrial DNA (mtDNA) [70].
Several studies have demonstrated the physiological importance of
PGC-1α in mitochondrial biogenesis in response to cold and exercise.
These external stimuli increase expression of PGC-1α leading to in-
creased expression of mitochondrial enzymes such as ATP synthase
(β-subunit), COX (cytochrome c oxidase) subunits (COX II and COX IV)
and δ-aminolevulinate synthase (δ-ALAS) [71,72]. Increased mitochon-
dria content allows for more efﬁcient thermogenesis in response to cold
and enhanced capacity to generate ATP to sustain exercise bouts. An iso-
form of PGC-1α, PGC-1β has also been identiﬁed, and although overex-
pression of this protein increased mitochondrial biogenesis and basal
oxygen consumptionmuch like PGC-1α, it was not induced by cold or ex-
ercise, suggesting alternate pathways for the induction of mitochondrial
biogenesis [73].
Aside from inﬂuencing the transcription of key players in the respira-
tory chain, PGC-1α also interacts with and upregulates the expression of
other transcription factors such as peroxisome proliferator-activated re-
ceptors (PPARs) [74], hormone receptors for estrogen and thyroxine, as
well as estrogen-related receptors (ERRs)α and γ [75]. ERRs are a partic-
ularly interesting set of nuclear receptors known as orphan receptors due
to a lack of an associated ligand [76]. These proteins are involved in
PGC-1α-dependent regulation of mitochondrial biogenesis. For ex-
ample, Schreiber et al. have demonstrated that over-expression of
PGC-1α results in upregulation of 151 genes that encodemitochondrial
proteins involved in manymetabolic functions of mitochondria such as
fatty acid β-oxidation (FAO), tricarboxylic acid cycle and oxidative
phosphorylation, as well as mitochondrial ribosomal machinery and
mitochondrial membrane transport proteins. This effect is inhibited by
siRNA targeted to ERRα, and conversely mimicked by overexpression
of ERRα [77]. Endonuclease G is regulated by ERRα and PGC-1α, and
its deletion results in cardiac hypertrophy and mitochondrial dysfunc-
tion [78]. Additional factors implicated in mitochondrial biogenesis in-
clude Lon protease and Hsp78 [79].
The expression of PGC-1α is controlled primarily through signaling
cascades. Calcineurin A-dependent (CnA) and Ca2+/calmodulin-
dependent protein kinase IV (CaMKIV) regulation of PGC-1α has beenwell characterized. CnA interacts with and activates myocyte enhancer
factors 2C and 2D (MEF2C and MEF2D), which regulate the transcription
of PGC-1α directly [80,81]. Furthermore, activation of PGC-1α results in
the upregulation of MEF2C and 2D, creating a feed forward loop that
allows PGC-1α to increase its own expression [82]. CaMKIV activates
PGC-1α by phosphorylating the transcription factor cAMP response ele-
ment (CRE)-binding protein (CREB). Phosphorylated CREB binds to pro-
moter elements of the PGC-1α gene to drive its expression [80]. Other
players controlling PGC-1α expression include p38 mitogen-activated
protein kinase (p38 MAPK) and AMP-activated protein kinase (AMPK).
p38MAPKactivity is increased following exercise, and this leads to the ac-
tivation of MEF2 and activating transcription factor 2 (ATF2), both of
which drive the expression of PGC-1α [83,84]. The activation of AMPK
in response to glucose depletion results in direct phosphorylation of
PGC-1α on threonine-177 and serine-538, which is crucial for the acti-
vation of PGC-1PGC-1α-dependent transcription from the PGC-1α pro-
moter [85].
Post-translational modiﬁcations such as phosphorylation and acety-
lation regulate PGC-1α activity. Kinases that have been implicated in
controlling PGC-1α activity include: AMPK and Akt during caloric re-
striction and p38 MAPK after endurance exercise [85–87]. Likewise,
p38MAPK increases the activity of PGC-1α by directly phosphorylating
threonine-262, serine-265, and threonine-268,which stabilizes the pro-
tein and disrupts the interaction between PGC-1α and its inhibitor
p160MBP [86,88]. Conversely, insulin inhibits the activity of PGC-1α
throughAkt, directly through phosphorylation of the serine-570 residue
on PGC-1α, and indirectly through phosphorylation of the Clk2 kinase
which in turn phosphorylates the C-terminal serine and threonine-rich
regions of PGC-1α, thereby decreasing its co-transcriptional activity [89,
90]. In an even more indirect manner, glycogen synthase kinase 3beta
(GSK3β) has also been shown to inhibit PGC-1α activity in response to
acute oxidative stress by increasing its proteasomal degradation and
inhibiting the activity of Sirt1, an NAD-dependent deacetylase thought
to activate PGC-1α [91]. This deacetylation event is crucial for the activa-
tion of PGC-1α, as the protein is very heavily acetylated by the acetyl-
transferase GCN5, inhibiting its activity and sequestering it in nuclear
foci distant from promoter regions of its target genes [92]. Sirt1 activity
is dependent upon the coenzyme nicotinamide adenine dinucleotide
(NAD+), and it is therefore highly sensitive to the changes in the ener-
getic state of the cell. Increased NAD+/NADH ratio—whichmay occur in
response to fasting, exercise or redox stress—activates Sirt1, leading to
PGC-1α deacetylation [93,94]. The result of this deacetylation is an in-
crease in the transcription of PGC-1α targets, leading to mitochondrial
biogenesis [95–97]. Interestingly, AMPK may once again play a role in
activating PGC-1α, not only by directly phosphorylating the protein,
but also indirectly by increasing NAD+ levels in the cell by fatty acid
oxidation, thereby increasing the activity of Sirt1 [97]. Other posttrans-
lational modiﬁcations such as ubiquitination or methylation also play a
role in modulating the activity of PGC-1α in response to energy
demands and oxidative stress, states that requiremitochondrial biogen-
esis [98].
Other proteins that play amajor part inmitochondrial biogenesis are
vascular endothelial growth factor (VEGF) and hypoxia-inducible factor
1 (HIF-1). VEGF is a key regulator of angiogenesis which involves sub-
stantial cell proliferation and production and remodeling of extracellular
matrix, processes which utilize large amounts of ATP. A study byWright
et al. demonstrated that VEGF stimulates mitochondrial biogenesis
by coordinated upregulation of OMM protein Tom70 and activation
of PGC-1α [99]. Interestingly, PGC-1α can also activate VEGF, by
coactivating ERR-α on conserved binding sites found in the promoter
and in a cluster within the ﬁrst intron of the VEGF gene, driving angio-
genesis in response to oxygen deprivation independently of HIF-1
[100]. HIF-1 is a master regulator of the adaptive response to hypoxia,
and as such is intimately linked to inducing mitochondrial biogenesis.
Several studies have linked PGC-1α and PGC-1β with HIF-1 activity.
O'Hagan et al. reported that mitochondrial biogenesis driven by the
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creased intracellular oxygen tension, permitting stabilization of HIF-1
and activation of a gene expression program to increase oxygen delivery
to the tissue [101]. Zhang et al. demonstrated that HIF-1 repressesmito-
chondrial biogenesis by controlling the transcription of PGC-1β through
downregulation of c-MYC transcription factor [102]. Fig. 2 highlights the
central role of PGC-1α in regulating mitochondrial biogenesis.
2.3. Interplay between mitophagy and mitochondrial biogenesis
Mitophagy and mitochondrial biogenesis are opposing forces that
govern the rate of mitochondrial turnover. This dynamic tension allows
for a readily adjustable population of mitochondria to match cellular
demands. Here we discuss several players that participate in this regu-
latory cross-talk.
Sirt1, an NAD-dependent lysine deacetylase, stimulates autophagy
directly by deacetylating various autophagy proteins including Atg7,
Atg5, and Atg8 (LC3) [103]. Sirt1 also deacetylates and activates PGC-1α
[104], thus positively regulating both mitophagy and biogenesis. Activa-
tion of PGC-1α is a key event in initiating mitochondrial biogenesis, but
no less important are the repressors of the process. Parkin-interacting
substrate (PARIS or ZNF746) has recently been identiﬁed as a direct tran-
scriptional repressor of PGC-1α [105]. The accumulation of PARIS in the
nucleus leads to direct inactivation of PGC-1α transcription and inhibition
of expression of PGC-1α-dependent genes. Aside from its role in facilitat-
ingmitophagy, Parkinwas shown to directly target PARIS for degradation
through the UPS. Events leading to the upregulation of mitophagy also
increase Parkin activitywhich then degrades PARIS, relieving repression
of mitochondrial biogenesis. This relationship establishes an intricateCold Exercise
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P38 MAPK Akt3
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MEF2C/D
CaMKIV
CnA
VEGF
P
PKA
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Ca++
PPARGC1A
ESRRA NFE2L1 PPARANFE2L2
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Fig. 2. PGC-1α regulation ofmitochondrial biogenesis. PGC-1α is considered amaster regulator
to environmental cues of fuel availability, fuel type, and cellular energy requirements. PGC-1α
MEF2, C/EBP, FoxO, CREB/CRTC, ERRγ, and MyoD/E2A. These factors in turn are activated by sp
and PKA, and suppressed by other signals including GCN5, AKT and SHP. In addition to transc
factors illustrated here. Ultimately, PGC-1α increases mitochondrial biogenesis and the capacisystem that links mitophagy with mitochondrial biogenesis. A model
illustrating this mechanism linking mitophagy with mitochondrial bio-
genesis is shown in Fig. 3. As the relationship between Parkin and PARIS
has thus far been identiﬁed only in neuronal models, an important and
exciting question remains as to whether this system exists in the heart.
Moreover, what are its implications in the setting of ischemia/reperfu-
sion injury?
Other repressors of mitochondrial biogenesis operate in less direct
manner. Nuclear co-repressor 1 (Ncor1) acts as a repressor of PPARγ,
PPARδ and ERR activity by interacting with histone deacetylases such
as HDAC3 and SIRT1 to maintain tonic repression of MEF2, PPARδ, and
ERR, thereby suppressing their participation in transcription programs
involving mitochondrial oxidative metabolism [106]. mTOR is a serine/
threonine kinase involved in numerous cell functions and can directly ac-
tivate PGC-1α to control mitochondrial biogenesis. During fasting, mTOR
is inhibited and autophagy/mitophagy is active. However, as lysosomal
degradation releases amino acids, mTOR is reactivated, suppressing
autophagy and supporting lysosomal and mitochondrial biogenesis
[107]. Eukaryotic translation initiation factor 4E (eIF4E)-binding proteins
(4E-BP) prevent translation of targets including nuclear encoded mito-
chondrial protein mRNAs including TFAM (transcription factor A, mito-
chondrial) and subunits of complex V and complex I. This inhibition is
lifted by the action of mTORC1 which inhibits 4E-BP proteins from bind-
ing their targets [108,109].
Autophagy and mitochondrial biogenesis are linked in both direc-
tions: PGC-1α induces the expression of transcription factor EB (TFEB)
[110], the master regulator of lysosome biogenesis and the autophagy
pathway [111]. TFEB and PGC-1α regulate one another's expression,
and the nutrient sensing regulator GCN5L1 suppresses both TFEB andNutrient Deprivation
AMP/ATP NAD+/NADH
C-1α
Ac
GCN5
AMPK SIRT1
mtDNA
TFAM
ofmitochondrial biogenesis. Transcriptional control of PGC-1α expression is closely linked
transcription is governed by multiple transcription factors (trans) including PPAR/RXR,
eciﬁc signal pathways including free fatty acids, AMPK, calcineurin, p38 MAPK, CaMK IV,
riptional control, PGC-1α activity is regulated by acetylation and phosphorylation by the
ty to perform OXPHOS, in particular, fatty acid oxidation.
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Fig. 3. The Parkin-PARIS axis coordinatesmitophagywithmitochondrial biogenesis. Basal state cellular homeostasis is characterized by balancedmitophagy andmitochondrial biogenesis
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own tail), autophagy and mitochondrial biogenesis, mitophagy and ly-
sosomal biogenesis, are elements of a system whose stability derives
from its dynamic regulation.
3. Mitochondrial turnover in the context of the organ and the
organism
3.1. Circadian rhythms and metabolic status
The circadian rhythm is an important regulator of cellular and
whole-body homeostasis. Disruption of this oscillatory system can
cause and aggravate several health issues. The connection between au-
tophagy and circadian rhythm was ﬁrst demonstrated in the 1970s
using electron microscopic analysis of different rat tissues to show that
the number of autophagic vacuoles changed over the course of the day
[113,114]. More recently an important work established a clear connec-
tion between circadian rhythm and the induction of autophagy [115].
Ma and collaborators showed that autophagy was upregulated during
the dark cycle, preceded by increasedmRNAexpression of autophagy ini-
tiators including Ulk1, and Bnip3, but not factors involved in later phases
of autophagy such as LC3B, Atg4, and Atg7. These events were regulated
by the transcription factor CCAAT-enhancer-binding protein β (C/EBPβ).
C/EBPβ is a liver clock protein that is tissue autonomous and regulates
whole body bioenergetics. The induction of autophagy usually promotes
mitophagy as well by upregulating mitochondria-targeting machinery
such as the autophagy adapter p62/SQSTM1 and the E3 ubiquitin–ligase
Parkin [116,117]. Mitochondrial biogenesis is also directly regulated by
the circadian clock, ensuring coordination of mitophagy with biogenesis
[118–120]. Conditions that disrupt the circadian clock will also impact
autophagy and mitochondrial biogenesis, with consequences for cell
and organ function; conversely, disruption of autophagy may affect the
clock [121].
The circadian rhythm is closely linked to eating behaviors (and diet
types), another important regulator of mitophagy in animals. Mitophagy
can be regulated by several different energy sensing stimuli: the availabil-
ity of AAs in a cell regulates mTOR activity; the glucose level in blood
regulates the release of insulin and glucagonwhich have opposing effects
on autophagy; and conditions such as metabolic syndrome and caloric
restriction regulate autophagy and mitophagy. Insulin suppressesmacroautophagy by activating the phosphatidyl-inositol triphosphate
(PIP3) cascade leading to the phosphorylation and activation of Akt and
subsequentlymTOR,which inhibits autophagy [122]. Usually high insulin
is followed by an increase in AAs in the cytosol, which also activates
mTOR, reinforcing the samepathway. Insulin also promotesmitochondri-
al fusion, whereas hypoglycemia and insulin resistance promote ﬁssion
[123–125]; both processes are essential to mitochondrial quality control.
The nutritional overload of a high fat diet suppresses autophagy and by
extension, mitophagy [126–128]. More recently, impaired mitochondrial
turnover in mice fed a high-fat diet was demonstrated using Timer pro-
tein targeted to mitochondria (MitoTimer). In this study, the authors
electroporated a MitoTimer construct under a constitutive promoter
into the skeletal muscle of mice which were then maintained on chow
or a high-fat diet. They observed a shift in the MitoTimer ratio to red, in-
dicating slower mitochondrial turnover [129]. Although they attributed
the red shift to increased oxidative stress, previous work showed that
MitoTimer maturation (color shift) was not sensitive to oxidants [130].
MitoTimer is a mitochondria-targeted ﬂuorescent molecular clock that
we developed as a tool to monitor mitochondrial turnover [59].
3.2. Cardiac development, cardioprotection and cardiac pathology
The development of stem cells into differentiated adult cells is a
tightly regulated process. Autophagy is involved in the maturation of
several different types of cells. Cardiomyocyte development is regulated
by the ﬁbroblast growth factor (FGF) signaling axis [131] and in skeletal
muscle FoxO is the responsible factor [132]. In both cases, autophagy
and mitophagy are tightly linked to differentiation and tissue plasticity
[131,133]. FGF suppresses autophagy and thereby prevents differentia-
tion of cardiac progenitors [134],while FoxO signaling induces autophagy
as part of the regeneration and growth of the muscle tissue. As discussed
above, mitophagy and biogenesis are tightly linked. These examples
highlight the importance of autophagy to tissue remodeling and repair
beyond degradation.
Genetic deletions of mitofusin-2 and PINK1 illustrate the importance
of mitophagy to heart development and homeostasis. Genetic deletion
of mitofusin-2 is embryonic lethal [135] and is essential in the heart not
only for mitochondrial dynamics [136], but also for ER–mitochondrial
calcium signaling [137], mitophagy [15], and autophagosome–lysosome
fusion [138]. Absence of PINK1 has profound consequences for postnatal
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[139].
Among themost potent interventions to protect the heart from ische-
mia and reperfusion injury are ischemic pre- and post-conditioning [140,
141]. Pre and post conditioning require autophagy to deliver the protec-
tion [142–144], although this is controversial in the brain [145,146].
Mitophagy is part of the autophagy response that is speciﬁcally required
for protection [13]. Other interventions that protect the heart against
ischemic injury, including chloramphenicol [147], caloric restriction
[148] simvastatin [12], and SAHA [149] all act through the autophagy/
mitophagy pathway, thus establishing autophagy/mitophagy as a hub
for cardiac protection. There are few direct inducers of autophagy;
rapamycin is anmTOR inhibitorwidely used as a drug to induce autoph-
agy. Rapamycin administration also decreased ischemia/reperfusion in-
jury [149,150] while upregulating autophagy. In chronic models of
heart failure, rapamycin also helps to ameliorate the phenotype [151].
Taken together, these facts support the beneﬁcial effects of inducing
autophagy.
In conditions where autophagy/mitophagy is impaired the opposite is
true: there is increased cardiac dysfunction and exacerbation of ischemia/
reperfusion injury in the setting of Parkin and PINK1 deletion [60,139],
deletion of macrophage migration inhibitor factor, an inducer of homeo-
static autophagy [152], and obesity [153]. Obesity [154] and diabetes
[155] disrupt normal energy metabolism, changing basal activation of
mTOR and other nutrient signaling cascades that regulate autophagy.
High fat diets are known to increase ischemia/reperfusion damage in
hearts [156,157] and there is now a signiﬁcant amount of work linking
the high fat diet to impaired autophagy [154] and accumulation of
dysfunctional mitochondria [158,159], highlighting the importance of
mitophagy to cardiac ischemia tolerance. The regulation of cardiac
mitophagy and physiological importance of this process is illustrated in
Fig. 4.
Autophagy may not always be a good thing in the heart. Infection of
juvenilemicewith Coxsackievirus B virus can exacerbate stress-induced
myocardial injury in adulthood [160]. Autophagy is needed for the
spread and reproduction of the virus [161], and virus-induced autophagy
triggers premature differentiation of cardiac-resident progenitor cells,Diabetes
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Fig. 4. Cardiac mitophagy regulation and signiﬁcance. Mitophagy is essential during
cardiomyocyte differentiation and for homeostatic mitochondrial turnover to maintain a
healthy population of mitochondria. During cardiac stress such as ischemia/reperfusion,
mitophagy functions to eliminate damaged mitochondria and reduce injury. Mitophagy
is also critical for ischemic preconditioning. Circadian rhythm regulates basal levels of
cardiac mitophagy. Nutrient overload, type 2 diabetes, obesity, and advanced age may
compromise cardiac autophagy and mitophagy, disrupting this adaptive physiological
response to stress.contributing to heart failure later in life [160]. Excessive autophagy has
been implicated in doxorubicin-mediated cardiac injury [162,163],
although other studies have reported a beneﬁcial role for autophagy
[164–167]. Interestingly, deletion of Nrf2, a transcriptional regulator of
autophagy andmitochondrial biogenesis, exacerbated doxorubicin tox-
icity, but this was reversed by overexpression of Atg5 [168]. They did
not examine whether restoring autophagy resulted in mitochondrial
biogenesis independent of Nrf2. It seems likely that unless mitophagy
is balanced by biogenesis, problems will ensue.
Mitochondrial biogenesis in the heart is tightly responsive to oxygen
tension. This is manifested at the transition from the fetal hypoxic state
to the postnatal aerobic environment, when HIF signaling is lost, thereby
favoring mitochondrial fusion and mitochondrial biogenesis [169].
During cardiac hypertrophy in response to aortic banding,mitochondrial
dysfunction and decreased biogenesis were noted [170]. Downregula-
tion of PGC-1α is observed in animal models of heart failure, but
attempts to restore mitochondrial biogenesis by overexpression of
PGC-1α did not improve cardiac function despite a modest increase in
mitochondrial content [171]. In fact, inducible overexpression of
PGC-1α in the heart resulted in abnormal mitochondrial morphology
and cardiomyopathy which was reversible upon the normalization of
PGC-1α levels [172]. These studies did not examine mitochondrial
autophagy. However, in a porcine study of renovascular hypertension,
hypertrophy was accompanied by the upregulation of mTOR, increased
abundance of markers of autophagy and mitophagy, and decreased
mitochondrial protein content, all of whichwere reversed by the angio-
tensin II receptor blocker valsartan [173]. The authors concluded that
hypertension increased autophagic clearance of mitochondria and
valsartan suppressed autophagy and restoredmitochondrial biogenesis.
However, because they did not measure autophagic ﬂux or p62 (a
surrogate marker of ﬂux), the data lend themselves to the opposite
interpretation: that hypertension impaired autophagic ﬂux, thereby
limiting mitochondrial biogenesis possibly through the Parkin/
PARIS/PGC-1α network. Evidence in support of the latter interpretation
is the ﬁnding that mTOR was strongly upregulated in the hypertensive
hearts, which would suppress autophagy. The observed increase in
Beclin 1 and LC3-II could reﬂect increased autophagy or impaired ﬂux.
Beclin 1 is known to interfere with autophagic ﬂux [174,175]. The
perinuclear accumulation of Parkin-decorated mitochondria is also in-
dicative of impaired lysosomal clearance of autophagosomes. This also
illustrates the importance of determining autophagic ﬂux and mito-
chondrial turnover before reaching a conclusion.4. Prospects and challenges for the future
Mitochondrial quality control depends upon mitophagy, biogenesis,
fusion, and ﬁssion, as well as selective protein quality control via AAA
proteases and chaperones. To date, most studies have explored mito-
chondrial dynamics (fusion/ﬁssion) and mitophagy (Parkin-dependent
and Parkin-independent mitochondrial autophagy). Mitophagy is in-
creasingly recognized to play a signiﬁcant role in the heart, yet in
order to maintain homeostasis, biogenesis must keep pace. Therefore,
approaches to monitoring mitochondrial turnover (the integrated out-
come of these four processes) are needed. Recent advances include the
analysis of the half-lives of mitochondrial proteins using mass spectrom-
etry analysis and deuterium labeling [55], mito-Keima, which can report
on mitochondria delivered to the lysosome [53], and MitoTimer, a ﬂuo-
rescent protein that can be used to monitor mitochondrial turnover [59,
129,130]. What lies ahead is the application of these tools to study phys-
iologic and pathologic processes in the heart.
A major challenge to overcome is imaging autophagy (or mitophagy)
in humans. Relatively few studies have examined autophagy in the
human heart, largely because of the challenges of accessing tissue, and
none have examined mitophagy, although animal studies indicate that
mitochondria are a frequent target of autophagy. There is a signiﬁcant
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mitophagy.
Still lacking is a thorough understanding of mitochondrial bio-
genesis: are all mitochondria equally capable of expanding and un-
dergoing ﬁssion to give rise to daughter mitochondria enriched for
newly-imported proteins and highly functional OXPHOS assem-
blies, or is there a subset of mitochondria that are specialized for
mitochondrial regeneration? Studies of MitoTimer suggest that
protein import preferentially takes place in mitochondria closest
to the nucleus [59,130]. This could be a trivial consequence of
mRNA proximity, and import of MitoTimer may not necessarily re-
ﬂect sites of biogenesis. It is exciting, however, to speculate that the
subpopulation of mitochondria most actively engaged in importing
newly-synthesized protein is indeed unique. Future studies may
shed light on this.
Mitochondrial protein import is essential for biogenesis, but is also
implicated in the regulation of mitophagy because PINK1 must transit
through the intermembrane space in order to be degraded by PARL.
Few studies have considered whether defective protein import is the
red ﬂag that signiﬁes a mitochondrion due for autophagic elimination.
It has not been demonstrated whether pre-amyloid oligomers might
disrupt mitochondrial protein import, yet this might explain the deteri-
oration of mitochondrial function (78) and impaired biogenesis (79)
that often accompanies Alzheimer's disease and potentially other pro-
tein folding disorders.We can expect that in the coming years investiga-
tors will integrate information exchange between mitochondria and
cytosol/nucleus, for which the TOM/TIM complex and VDAC serve as
important carriers.
A key to mitochondrial homeostasis is the ability to remove and
replace components throughout the network: not only proteins, but
also lipids and mtDNA copies. In the heart, where mitochondrial fusion
and ﬁssion events seem to occur with a frequency approximately equal
to the rate of turnover of the entire organelle, intra-mitochondrial deg-
radation and protein import generalized across the network may play a
larger role than regionally restricted biogenesis followed by redistribu-
tion via fusion events. The intriguing observation that proteins in
subsarcolemmal mitochondria turn over faster than in interﬁbrillar mi-
tochondria suggests that different turnover mechanisms may operate
within the same cell. The thought-provoking discovery that individual
mitochondrial proteins have widely differing half-lives raises questions
about the mechanisms governing this process; regulation of these dif-
ferent mechanisms for degrading mitochondrial proteins may be quite
complex, and their contribution to disease phenotypes will be equally
so. The importance of mitochondrial protein import is emerging:
recently it was reported that redirecting a mutant form of alanine:
glyoxalate aminotransferase from mitochondria to peroxisomes cor-
rects primary hyperoxaluria 1 (PH1), a lethal metabolic disease [176].
Enzymes that may trafﬁc either to mitochondria or peroxisomes can
have radically different consequences depending on their location; the
potential signiﬁcance of this process for heart disease is unknown at
present.
Yet another emerging area is the role of miRNAs in regulating
autophagy and mitochondrial biogenesis. miRNA-149 inhibits
poly(ADP-ribose) polymerase-2 (PARP-2), thereby allowing an in-
crease in cellular NAD+ and activation of sirtuin-1, leading to mito-
chondrial biogenesis [177]. miR-27a and miR-27b impair
mitochondrial biogenesis [178]. miRNAs also regulate the Nrf2
pathway [179] and autophagy [180–184]. Elucidating the contribu-
tion of miRNAs to the dynamic regulation of mitophagy and biogen-
esis will require a systems biology approach.
Many open questions remain to be resolved, but technical advances
continue to make new discoveries possible. The advent of novel gene
therapy approaches, cell permeable proteins, and small molecule
therapeutics targeting mitochondrial quality control mechanisms hold
promise for treating a variety of diseases from the perspective of the un-
derlying mitochondrial dysfunction. It is not too farfetched to envisionmitochondrial medicine becoming a medical specialty as much as sur-
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Mitochondrial Mysteries
Roberta A. Gottlieb
We know so much yet understand so little
About mitochondrial ox-phos and fusion and ﬁssion,
Mitochondrial autophagy and biogenesis.
MitoTimer and lenses have given us celluvision.
Though heart cells live years it's quite different within:
Mitochondrial life is counted in weeks.
Outer and inner membrane proteins vary yet more
In their lifespans revealed by mass spectrum peaks.
Protein import must match what's inside,
Lest proteins unfold and fall prey to Lon.
The peptides escape to the cytosol
To trigger transcription of chaperones.
Try we must to describe and deﬁne
The complex nature of the proteome,
As mitochondria expand and divide,
Fragment and fall into autophagosomes.
Yet for all we know and all we learn
The mysteries grow and questions expand
Like Mandelbrot sets of fractal images,
We see the work of divinity's hand.References
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